Karyopharm Therapeutics Inc. recently delivered a corporate presentation highlighting their focus on the transformative opportunity in treating myelofibrosis with selinexor (XPOVIO®/NEXPOVIO®). The presentation detailed the growing global demand for selinexor, which is now approved in over 45 countries. The company anticipates a peak annual revenue opportunity of up to $1 billion in myelofibrosis. Karyopharm is conducting the Phase 3 SENTRY trial for selinexor in myelofibrosis, with top-line data expected in late 2025/early 2026. Additionally, the company continues to invest in its pipeline, including in endometrial cancer and multiple myeloma. You can access the full presentation through the link below.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。